The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo

Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab. Despite additive clinical effects, previous studies have paradoxically demonstrated that targeted therapies potentially negativel...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunol
Päätekijät: Palazzo, Adam, Herter, Sylvia, Grosmaire, Laura, Jones, Randy, Frey, Christian R., Limani, Florian, Bacac, Marina, Umana, Pablo, Oldham, Robert J., Marshall, Michael J. E., Cox, Kerry L., Turaj, Anna H., Cragg, Mark S., Klein, Christian, Carter, Matthew J., Tannheimer, Stacey
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AAI 2018
Aiheet:
Clinical and Human Immunology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5857647/
https://ncbi.nlm.nih.gov/pubmed/29453281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1700323
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia